Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer — RT-PACE  

Endometrial Carcinoma Clinical Trial

Official title: RT-PACE: A Pilot Study of Adjuvant Hypo-Fractionated Radiotherapy for Non-Metastatic Cervical and Endometrial Cancer

Status Recruiting

Clinical Trial Summary

This clinical trial studies the feasibility of using hypo-fractionated radiotherapy for the treatment of cervical or endometrial cancer. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.

Clinical Trial Description

PRIMARY OBJECTIVE:

I. To establish the trial as feasible and to assess the impact upon acute gastrointestinal toxicity in the third week of pelvic radiotherapy following a hypo-fractionated schedule.

SECODARY OBJECTIVES:

I. To estimate impact upon acute urinary toxicity. II. To estimate impact upon patient reported gastrointestional toxicity. III. To assess acute quality of life following treatment. IV. To quantify acute financial toxicity following treatment. V. To assess satisfaction with decision-making following treatment. VI. To assess the overall survival throughout 3 years of post-treatment follow-up.

OUTLINE:

Patients undergo hypo-fractionated radiotherapy over 3 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 1, 3, and 6 months and then at 1, 2, and 3 years. ;

Related Conditions & MeSH terms

• Carcinoma
• Cervical Carcinoma
• Endometrial Carcinoma
• Endometrial Neoplasms

• NCT number: NCT05139368
• Study type: Interventional
• Source: University of Utah
• Contact: Rachel Kingsford
• Phone: 801-585-0115
• Email: rachel.kingsford@hci.utah.edu
• Status: Recruiting
• Phase: N/A
• Start date: November 11, 2021
• Completion date: November 15, 2027